SCHEMBL4450367

SCHEMBL4450367

COC(=O)c1cc(Cl)cnc1Cc1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MAPK1 P28482 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.44
SNCA P37840 2/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
HSP90AA1 P07900 1/20 0.41
HSP90B1 P14625 1/20 0.41
PDE10A Q9Y233 1/20 0.40
PLA2G2A P14555 2/20 0.40
RAB9A P51151 3/20 0.40
GAA P10253 1/20 0.40
STAT1 P42224 1/20 0.40
NPC1 O15118 2/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4447411 0.89 LMNA (0.46) KDM4ESMN1; SMN2L3MBTL1HPGDMAOB
SCHEMBL4443153 0.86 HSP90AA1 (0.47) KDM4EALDH1A1SMN1; SMN2L3MBTL1HPGD
SCHEMBL8274376 0.86 KDM4E (0.49) KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1
SCHEMBL4446764 0.86 ADRA1D (0.46) ALDH1A1SMN1; SMN2HSP90AA1PTGER4
SCHEMBL4448337 0.85 BRS3 (0.47) ALDH1A1SMN1; SMN2L3MBTL1SNCARAB9A
SCHEMBL4448354 0.83 PTGER4 (0.58) PTGER4PTGER2
SCHEMBL4450410 0.83 MRGPRX4 (0.46) MRGPRX4SNCAPTGER4PTGER2
SCHEMBL28762615 0.83 SNCA (0.43) ALDH1A1SMN1; SMN2L3MBTL1SNCARAB9A
SCHEMBL5366100 0.79 KDM4E (0.47) KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1
SCHEMBL1324766 0.77 RPS6KB1 (0.46) ALDH1A1SMN1; SMN2RAB9ANPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663979-B1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2013-10-09 EP disclosed
CN-1867551-B Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists RAQUALIA PHARMA INC 2013-09-11 CN disclosed
WO-2005102389-A9 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2009-04-30 WO disclosed
WO-2005102389-A9 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2009-04-30 WO disclosed
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PFIZER, INC. 2009-02-05 US disclosed
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PFIZER, INC. 2009-02-05 US disclosed
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PFIZER, INC. 2009-02-05 US disclosed
US-7238714-B2 Aryl or heteroaryl amide compounds PFIZER JAPAN, INC. (JP) 2007-07-03 US disclosed
CN-1946391-A Combinations comprising alpha-2-delta ligands PFIZER PROD INC (US) 2007-04-11 CN disclosed
EP-1740211-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-01-10 EP disclosed
CN-1867551-A Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists PFIZER (US) 2006-11-22 CN disclosed
EP-1663979-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2006-06-07 EP disclosed
WO-2005102389-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-03 WO disclosed
WO-2005102389-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-03 WO disclosed
US-20050065188-A1 Aryl or heteroaryl amide compounds ASKAT INC. (JP) 2005-03-24 US disclosed
WO-2005021508-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065188-A1 Aryl or heteroaryl amide compounds HRH2, PTGER1, LTB4R2 KDM4E 875/4885ALDH1A1 860/4885SMN1; SMN2 3422/4885
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PTGER4, PTGER2, OPRL1 KDM4E 1957/4885ALDH1A1 1861/4885SMN1; SMN2 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.